News

Gene activity analysis of whole blood collected from people with pulmonary arterial hypertension (PAH) identified three patient subgroups associated with distinct clinical features and outcomes, a study concluded. These findings may provide molecular insights into the development of PAH, improve disease risk assessments, and potentially guide individual treatment strategies,…

Team PHenomenal Hope’s research fund, the PHenomenal Impact Fund for Global PH Research, will help finance pulmonary hypertension (PH) research for the fourth consecutive year. “Team PHenomenal Hope [Team PH] actively seeks ways to improve the quality of life for those with Pulmonary Hypertension by building community, providing…

Increased lung arterial obstruction is significantly associated with greater airflow obstruction in people with chronic thromboembolic pulmonary hypertension (CTEPH) and without a smoking history, a study shows. Notably, airflow obstruction, reflected by a reduced ability to exhale quickly, was lessened with reduced arterial obstruction and improved blood flow following…

The levels of Piezo1, an ion channel that senses membrane tension in cells, was found to be increased in the lung blood vessels of patients with idiopathic pulmonary arterial hypertension (PAH) and in animal models of pulmonary hypertension (PH), a study says. Research showed that these higher levels…

In addition to lowering blood pressure, treatments for pulmonary arterial hypertension (PAH) probably work at least in part by preventing physical changes in the architecture of the lung’s blood vessels that are associated with the progression of the disease, according to a study. “Our findings suggest that the beneficial…

People with pulmonary hypertension are at increased risk of developing cancer, especially lung and skin cancers, a new study indicates. The study, “Pulmonary hypertension is associated with an increased incidence of cancer diagnoses,” was published in the journal Pulmonary Circulation. Pulmonary hypertension (PH) refers to…

Tenax Therapeutics has completed a pharmacological assessment of TNX-201, the company’s new oral formulation of imatinib for pulmonary arterial hypertension (PAH), in healthy volunteers. The assessment included comparisons against Gleevec, another oral formulation of imatinib sold by Novartis that is approved to treat certain blood cancers, but was…

Pulmonary Hypertension News brought you the latest coverage of advances in treatment, clinical trials, and scientific research related to pulmonary hypertension (PH) throughout 2021. We look forward to continuing to report more news to patients, family members, and caregivers dealing with PH in the new year. Here are the…

Care at a specialty center is tied to a lower risk of hospitalization for people with heart failure with preserved ejection fraction (HFpEF) who have pulmonary hypertension, according to a new study. The study, “Improved Hospitalization Rates in a Specialty Center for Heart Failure with Preserved Ejection Fraction…

Children with pulmonary arterial hypertension (PAH) report poorer health-related quality of life (HRQoL) than their peers, a study shows. Results also suggest that worse HRQoL in children with PAH is linked with more severe depression in their parents, which suggests that providing support to families may help to improve…

Claritas Pharmaceuticals now has exclusive worldwide rights to develop and market R-107 — a liquid form of nitric oxide — for the treatment of pulmonary diseases such as pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN). In its announcement…

PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil (PB1046), due to the impact of the COVID-19 pandemic on medicine manufacturing, associated supply, and enrollment rates. The company said it would conduct an analysis of the trial’s results and,…